Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy

Background

Strategies that enhance the function of T cells are critical for immunotherapy.

Methods

Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of PD-1.

Results

We showed that the gene knockout of PD-1 by electroporation of plasmids encoding sgRNA and Cas9 was technically feasible. The disruption of PD-1 resulted in significant reduction of PD-1 expression but didn't affect the viability of primary human T cells. Cellular immune response of the gene modified T cells was characterized by up-regulated IFN-γ production and enhanced cytotoxicity.

Conclusions

These results suggest that we have established an approach for efficient checkpoint inhibitor disruption, providing a new strategy for targeting checkpoint inhibitors to improve the efficacy of T cell based adoptive therapies.

figure1
figure2
figure3

References

  1. 1.

    Topalian SL, Hodi S, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012, 366: 2443-2454.

    PubMed  CAS  PubMed Central  Article  Google Scholar 

  2. 2.

    Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, et al: Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther. 2014, 21 (3): 262-271.

    PubMed  CAS  Article  Google Scholar 

  3. 3.

    Lloyd A, Vickery ON, Laugel B: Beyond the antigen receptor: editing the genome of T cells for cancer adoptive cellular therapies. Front Immunol. 2013, 4: 221-

    PubMed  CAS  PubMed Central  Article  Google Scholar 

  4. 4.

    Li W, Teng F, Li T, Zhou Q: Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. Nat Biotechnol. 2013, 31 (8): 684-686.

    PubMed  CAS  Article  Google Scholar 

  5. 5.

    Shen B, Zhang J, Wu H, Wang J, Ma K, Li Z, et al: Generation of gene- modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 2013, 23: 720-723.

    PubMed  CAS  PubMed Central  Article  Google Scholar 

  6. 6.

    Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al: Generation of gene-modified Cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014, 156 (4): 1-8.

    Article  Google Scholar 

  7. 7.

    Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al: Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014, 11 (4): 399-402.

    PubMed  CAS  Article  Google Scholar 

  8. 8.

    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2014, 366 (26): 2443-2454.

    Article  Google Scholar 

  9. 9.

    Iwamura K, Kato T, Miyahara Y, Naota H, Mineno J, Ikeda H, et al: siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T cell effector functions. Gene Therapy. 2012, 19 (10): 959-966.

    PubMed  CAS  Article  Google Scholar 

  10. 10.

    Chicaybam L, Sodre AL, Curzio BA, Bonamino MH: An efficient low cost method for gene transfer to T lymphocytes. PLOS One. 2013, 8: e60298-

    PubMed  CAS  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

The authors thank the entire Huang Lab and Liu Lab for their support and advice. This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81172281, 81000980, 81220108023, 81172094).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Zhengyun Zou.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Su, S., Liu, B. & Zou, Z. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy. j. immunotherapy cancer 3, P53 (2015). https://doi.org/10.1186/2051-1426-3-S2-P53

Download citation

Keywords

  • Public Health
  • Immune Response
  • Cellular Immune Response
  • Gene Knockout
  • Mediate Approach